Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Early treatment reduces viral reservoirs but does not prevent rebound

Antiretroviral therapy started during the first several days after infection limited dissemination of an HIV-like virus throughout the body and establishment of cellular and tissue reservoirs in monkeys,

Published
21 March 2014
By
Liz Highleyman
Early antiretroviral therapy may limit gut damage and immune activation

Starting antiretroviral therapy (ART) at the earliest stage of HIV infection can help prevent immune cell dysregulation that contributes to destruction of the gut lining and promotes

Published
20 March 2014
By
Liz Highleyman
You're Not Alone: Medical Conspiracies Believed By Many

About half of American adults believe in at least one medical conspiracy theory, but some conspiracy theories have much more traction than others, a survey shows. Three times as many people believe U.S. regulators prevent people from getting natural cures as believe that a U.S. spy agency infected African Americans with HIV.

Published
19 March 2014
From
Reuters
HIV Cure Research at CROI 2014

A round-up of cure research at the 21st Conference on Retroviruses and Opportunistic Infections.

Published
17 March 2014
From
BETA blog
Very different levels of PrEP uptake and adherence in three US cities, demonstration project finds

One of the first studies of open-label pre-exposure prophylaxis (PrEP) for at-risk gay men in three US cities shows that although the proportion of those initially offered or

Published
17 March 2014
By
Gus Cairns
AIDS No Longer Among Top Ten Causes Of Death In NYC

For the first time since the HIV epidemic exploded more than a generation ago, AIDS is no longer one of the top 10 causes of death in New York City.

Published
14 March 2014
From
New York Daily News
Heart attack link to abacavir persists in D:A:D study

The nucleoside (NRTI) drug abacavir (Ziagen also in Kivexa/Epzicom) continues to be associated with a near-doubling of the risk of a heart attack, according to the latest

Published
14 March 2014
By
Gus Cairns
Can Gilead Dominate The HIV Drug Market Again in 2014?

The development of combination therapies provides Gilead with a long-lasting HIV product portfolio that should allow the company to maintain its leadership for the foreseeable future. As a result, Gilead is able to reinvest in its product portfolio.

Published
13 March 2014
From
Motley Fool
Efavirenz-based ART matches lopinavir/ritonavir for perinatal HIV treatment

Pregnant women taking efavirenz-based antiretroviral therapy had significantly better virologic outcomes at the time of delivery compared to those taking lopinavir/ritonavir in a randomised study in rural

Published
12 March 2014
By
Carole Leach-Lemens
New NNRTI doravirine matches efavirenz for first-line HIV treatment

The next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (formerly MK-1439) showed potent antiretroviral activity and good tolerability in combination with tenofovir/FTC (the drugs in Truvada) in a dose-finding

Published
11 March 2014
By
Liz Highleyman

Filter by country